Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 5/20 | 0.36 |
| ▸ | NT5M | Q9NPB1 | 1/20 | 0.34 |
| ▸ | RNASE1 | P07998 | 1/20 | 0.34 |
| ▸ | BCHE | P06276 | 1/20 | 0.34 |
| ▸ | TK2 | O00142 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | ALB | P02768 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20394000 | 0.89 | TK1 (0.40) | TK1TK2LMNAALBPKM | |
| SCHEMBL25967800 | 0.85 | TK1 (0.40) | TK1NT5MRNASE1BCHETK2 | |
| SCHEMBL20394002 | 0.84 | TK1 (0.36) | TK1NT5MRNASE1BCHELMNA | |
| SCHEMBL20394003 | 0.84 | TK1 (0.36) | TK1NT5MRNASE1BCHELMNA | |
| SCHEMBL23152977 | 0.83 | TK1 (0.41) | TK1NT5MRNASE1BCHETK2 | |
| SCHEMBL26135487 | 0.83 | TK1 (0.42) | TK1NT5MRNASE1BCHETK2 | |
| SCHEMBL26135489 | 0.83 | TK1 (0.42) | TK1NT5MRNASE1BCHETK2 | |
| SCHEMBL20394037 | 0.83 | TK1 (0.36) | TK1NT5MRNASE1BCHETK2 | |
| SCHEMBL1097256 | 0.81 | TK1 (0.39) | TK1NT5MRNASE1BCHETK2 | |
| SCHEMBL20394059 | 0.81 | BCHE (0.39) | BCHELMNACYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10961269-B2 | Bridged nucleic acid GuNA, method for producing same, and intermediate compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2021-03-30 | — | — | US | disclosed |
| US-20180251488-A1 | CROSSLINKED NUCLEIC ACID GUNA, METHOD FOR PRODUCING SAME, AND INTERMEDIATE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2018-09-06 | — | — | US | disclosed |
| EP-3351548-A1 | CROSSLINKED NUCLEIC ACID GUNA, METHOD FOR PRODUCING SAME, AND INTERMEDIATE COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2018-07-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10961269-B2 | Bridged nucleic acid GuNA, method for producing same, and intermediate compound | POLRMT, POLM, NSUN2 | TK1 572/4885NT5M 4501/4885RNASE1 213/4885 |
| US-20180251488-A1 | CROSSLINKED NUCLEIC ACID GUNA, METHOD FOR PRODUCING SAME, AND INTERMEDIATE COMPOUND | NSUN2, RNMT, POLRMT | TK1 1806/4885NT5M 3308/4885RNASE1 291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.